Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease

Jodie L. Babitt, Despina Sitara

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: Recent research has revealed that regulation of the bone-secreted hormone fibroblast growth factor 23 (FGF23) is not limited to classical mineral factors. Specifically, bidirectional relationships have been described between FGF23 production and anemia, iron status, and inflammation. Here, we will review the latest published articles on the crosstalk between FGF23 and the aforementioned nonclassical factors. RECENT FINDINGS: It has been recently reported that erythropoietin, iron deficiency, and inflammation increase FGF23 production and metabolism. Moreover, FGF23 promotes anemia and regulates inflammatory responses. These findings are particularly important in the setting of chronic kidney disease which is characterized by elevated FGF23 levels and several associated comorbidities. SUMMARY: Regulation of FGF23 is complex and involves many bone and renal factors. More recently, erythropoietin, iron deficiency, and inflammation have been also shown to affect FGF23 transcription and cleavage. Importantly, FGF23 has emerged as a regulator of erythropoiesis, iron metabolism, and inflammation. These findings provide novel and important insights into the pathophysiologic mechanisms of chronic kidney disease and may present new opportunities for therapeutic clinical interventions.

Original languageEnglish (US)
Pages (from-to)304-310
Number of pages7
JournalCurrent opinion in nephrology and hypertension
Volume28
Issue number4
DOIs
StatePublished - Jul 1 2019

Fingerprint

Kidney Diseases
Erythropoietin
Iron
Inflammation
Chronic Renal Insufficiency
Anemia
fibroblast growth factor 23
Bone and Bones
Erythropoiesis
Minerals
Comorbidity
Hormones
Kidney

ASJC Scopus subject areas

  • Internal Medicine
  • Nephrology

Cite this

Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease. / Babitt, Jodie L.; Sitara, Despina.

In: Current opinion in nephrology and hypertension, Vol. 28, No. 4, 01.07.2019, p. 304-310.

Research output: Contribution to journalArticle

@article{5fee4ab7c028413fb6e01b8d587013f3,
title = "Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease",
abstract = "PURPOSE OF REVIEW: Recent research has revealed that regulation of the bone-secreted hormone fibroblast growth factor 23 (FGF23) is not limited to classical mineral factors. Specifically, bidirectional relationships have been described between FGF23 production and anemia, iron status, and inflammation. Here, we will review the latest published articles on the crosstalk between FGF23 and the aforementioned nonclassical factors. RECENT FINDINGS: It has been recently reported that erythropoietin, iron deficiency, and inflammation increase FGF23 production and metabolism. Moreover, FGF23 promotes anemia and regulates inflammatory responses. These findings are particularly important in the setting of chronic kidney disease which is characterized by elevated FGF23 levels and several associated comorbidities. SUMMARY: Regulation of FGF23 is complex and involves many bone and renal factors. More recently, erythropoietin, iron deficiency, and inflammation have been also shown to affect FGF23 transcription and cleavage. Importantly, FGF23 has emerged as a regulator of erythropoiesis, iron metabolism, and inflammation. These findings provide novel and important insights into the pathophysiologic mechanisms of chronic kidney disease and may present new opportunities for therapeutic clinical interventions.",
author = "Babitt, {Jodie L.} and Despina Sitara",
year = "2019",
month = "7",
day = "1",
doi = "10.1097/MNH.0000000000000514",
language = "English (US)",
volume = "28",
pages = "304--310",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Crosstalk between fibroblast growth factor 23, iron, erythropoietin, and inflammation in kidney disease

AU - Babitt, Jodie L.

AU - Sitara, Despina

PY - 2019/7/1

Y1 - 2019/7/1

N2 - PURPOSE OF REVIEW: Recent research has revealed that regulation of the bone-secreted hormone fibroblast growth factor 23 (FGF23) is not limited to classical mineral factors. Specifically, bidirectional relationships have been described between FGF23 production and anemia, iron status, and inflammation. Here, we will review the latest published articles on the crosstalk between FGF23 and the aforementioned nonclassical factors. RECENT FINDINGS: It has been recently reported that erythropoietin, iron deficiency, and inflammation increase FGF23 production and metabolism. Moreover, FGF23 promotes anemia and regulates inflammatory responses. These findings are particularly important in the setting of chronic kidney disease which is characterized by elevated FGF23 levels and several associated comorbidities. SUMMARY: Regulation of FGF23 is complex and involves many bone and renal factors. More recently, erythropoietin, iron deficiency, and inflammation have been also shown to affect FGF23 transcription and cleavage. Importantly, FGF23 has emerged as a regulator of erythropoiesis, iron metabolism, and inflammation. These findings provide novel and important insights into the pathophysiologic mechanisms of chronic kidney disease and may present new opportunities for therapeutic clinical interventions.

AB - PURPOSE OF REVIEW: Recent research has revealed that regulation of the bone-secreted hormone fibroblast growth factor 23 (FGF23) is not limited to classical mineral factors. Specifically, bidirectional relationships have been described between FGF23 production and anemia, iron status, and inflammation. Here, we will review the latest published articles on the crosstalk between FGF23 and the aforementioned nonclassical factors. RECENT FINDINGS: It has been recently reported that erythropoietin, iron deficiency, and inflammation increase FGF23 production and metabolism. Moreover, FGF23 promotes anemia and regulates inflammatory responses. These findings are particularly important in the setting of chronic kidney disease which is characterized by elevated FGF23 levels and several associated comorbidities. SUMMARY: Regulation of FGF23 is complex and involves many bone and renal factors. More recently, erythropoietin, iron deficiency, and inflammation have been also shown to affect FGF23 transcription and cleavage. Importantly, FGF23 has emerged as a regulator of erythropoiesis, iron metabolism, and inflammation. These findings provide novel and important insights into the pathophysiologic mechanisms of chronic kidney disease and may present new opportunities for therapeutic clinical interventions.

UR - http://www.scopus.com/inward/record.url?scp=85067294909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067294909&partnerID=8YFLogxK

U2 - 10.1097/MNH.0000000000000514

DO - 10.1097/MNH.0000000000000514

M3 - Article

C2 - 31145704

AN - SCOPUS:85067294909

VL - 28

SP - 304

EP - 310

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 4

ER -